Lipocine Inc. (LPCN) has a negative trailing P/E of -1.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 17.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -85.36%, forward earnings yield 5.86%.
Criteria proven by this page:
Overall SharesGrow Score: 48/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.5 | 0.59 | 2.58 | 0.00 | - |
| 2017 | -3.3 | -4.45 | 3.62 | 0.00 | - |
| 2018 | -2.4 | 0.05 | 2.92 | 64.39 | - |
| 2019 | -0.8 | 0.09 | 1.59 | 60.44 | - |
| 2020 | -3.6 | 0.15 | 4.89 | 0.00 | - |
| 2021 | -87.7 | 0.90 | 1.22 | 3.45 | - |
| 2022 | -3.1 | 0.00 | 0.95 | 67.61 | - |
| 2023 | -0.9 | -0.02 | 0.72 | -5.16 | - |
| 2024 | 3,119.5 | -31.18 | 1.24 | 2.33 | - |
| 2025 | -4.5 | 0.00 | 3.02 | 22.14 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-17.68 | $0.00 | $-18.97M | - |
| 2017 | $-17.85 | $0.00 | $-20.98M | - |
| 2018 | $-9.28 | $428.03K | $-11.66M | -2724.1% |
| 2019 | $-8.54 | $164.99K | $-13.01M | -7883.7% |
| 2020 | $-6.40 | $0.00 | $-20.96M | - |
| 2021 | $-0.12 | $16.14M | $-634.4K | -3.9% |
| 2022 | $-2.05 | $500K | $-10.76M | -2151.7% |
| 2023 | $-3.14 | $-2.85M | $-16.35M | - |
| 2024 | $0.00 | $11.2M | $8.35K | 0.1% |
| 2025 | $-1.69 | $1.98M | $-9.63M | -487.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.19 | $-2.52 – $-1.85 | $650K | $574.07K – $725.93K | 1 |
| 2027 | $-1.35 | $-1.56 – $-1.14 | $1.09M | $962.66K – $1.22M | 1 |
| 2028 | $-1.10 | $-1.27 – $-0.93 | $2.47M | $2.47M – $2.47M | 1 |
| 2029 | $-0.60 | $-0.69 – $-0.51 | $8.53M | $7.53M – $9.53M | 1 |
| 2030 | $0.15 | $0.13 – $0.17 | $20.64M | $18.22M – $23.05M | 1 |
